Funding

California-Based Inocras Scores $31M in Series B-3 Financing

Aug 4, 2026 | By Devin Jacobs

SUMMARY

Inocras raised $31 million in a Series B-3 financing round to support its growth.
Inocras is a bioinformatics company that uses whole-genome sequencing and AI-powered analytics to deliver precision oncology and genomic insights.
The funding will expand the company's U.S. commercial operations and scale its whole-genome sequencing capabilities.

Inocras Inc., a San Diego, CA-based bioinformatics-led company leveraging whole-genome data and proprietary analytics to deliver curated insights, has raised $31 million in a Series B-3 financing round.

The round saw the backers NDS Corporation, Aimed Bio, IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities, DSC Investment, Dunamu & Partners, and InterVest.

The fresh funding will support Inocras’ expansion of its commercial and operational infrastructure in the United States and help scale its whole-genome sequencing capabilities.

Funding Snapshot

Metric	Details
Fundraise Amount	$31 million
Funding Round	Series B-3
Valuation	Undisclosed
Company	Inocras Inc.
Sector	Bioinformatics / Precision Health
Headquarters	San Diego, California, US

RECOMMENDED FOR YOU

Funding

NeuralTrust Raises $20M in Seed Funding Led by Alstin Capital

Devin Jacobs

Jun 18, 2026

Funding

Caldera Therapeutics Launches with $112.5M in Total Capital

Startuprise

Jan 15, 2026

Funding

[Funding News] Endless Health Secures $4.5 Million Series Seed Funding

Team SR

Jul 22, 2024

About Inocras

Founded in 2020 by Young Seok Ju and Jeong Seok Lee, Inocras is a bioinformatics-led company focused on using whole-genome data and proprietary analytics to improve precision health.

The company combines comprehensive genomic data with automated interpretation tool's to generate clinically relevant insights for oncology, and rare disease applications.

Core offerings include:

Whole-genome sequencing
Precision oncology solutions
Cancer genomic profiling
Molecular residual disease detection

Core Technologies / Products / Services

Capability/Product	Application/Use Case
Whole-Genome Sequencing	Comprehensive analysis of cancer genomes
CancerVision™	Comprehensive tumor profiling
MRDVision™	Molecular residual disease detection
Proprietary Bioinformatics	Automated genomic data interpretation

Leadership Comments

“We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases,” said Jehee Suh, CEO of Inocras. “Our next objective is to bring that clinical experience to the United States and help make whole-genome analysis a standard part of cancer care. This financing gives us the resources to expand our clinical presence, support adoption within hospitals and build the evidence and infrastructure required to achieve that goal.”